Admin-Core-001

管理核心-001

• 批准号: 10942885
• 负责人: Boyi Gan
• 金额: $ 18.23万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-01 至 2027-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10942885
• 关键词: Achievement; Administrative Supplement; Advisory Committees; Basic Science; Benchmarking; Cancer Patient; Clinical; Cloning; Collaborations; Combined Modality Therapy; Communication; Data; Development; Direct Costs; Doctor of Philosophy; Ensure; Esophageal Adenocarcinoma; Evaluation; Faculty; Funding; Genomics; Goals; Guidelines; Human; Hypoxia; Image; Imaging Device; Immunotherapy; Infrastructure; Institution; Intellectual Property; Iron; Knowledge; Leadership; Malignant neoplasm of esophagus; Malignant neoplasm of lung; Measures; Metabolic; Mus; Myeloid Cells; National Cancer Institute; Office of Administrative Management; Patients; Performance; Policies; Pre-Clinical Model; Principal Investigator; Process; Production; Progress Reports; Radiation; Radiation therapy; Radiation-Sensitizing Agents; Reporter Genes; Research; Research Project Grants; Resistance; Resource Sharing; Resources; Risk; Role; Sampling; Students; Technology; Testing; Therapeutic Agents; Training; Transfection; Transgenic Organisms; Translating; Translational Research; Wages; Work; Xenograft Model; anticancer research; cancer cell; cancer type; chemoradiation; cohort; conflict resolution; data management; data sharing; esophageal cancer patient; interest; meetings; member; molecular imaging; neoplastic cell; novel therapeutics; outreach; peer; programs; radiation resistance; stable cell line; standard of care; therapy resistant; tool; tumor; tumor growth; tumor hypoxia; web site

ADMINISTRATIVE CORE – SUMMARY The proposed Acquired Resistance to Therapy and Iron (ARTI) Center is focused on the role of ferroptosis in acquired resistance to radiation therapy. Radiation therapy is used to treat approximately 50% of cancer patients and is standard of care treatment for lung cancer and esophageal cancer patients. The ARTI Center will focus on these cancer types and comprise three research projects. Project 1 will focus on identifying the mechanisms of ferroptosis in acquired resistance to radiation therapy and testing ferroptosis inducers (FINs) as radiosensitizers. Project 2 will focus on determining whether hypoxia-induced resistance to ferroptosis contributes to acquired tumor resistance to radiation therapy and whether FINs re-sensitize hypoxic tumor cells to radiation treatment. Project 3 will focus on understanding the role of genomic and microenvironment factors in acquired resistance to ferroptosis to chemoradiation in esophageal adenocarcinoma. The three research projects will be supported by one shared Molecular Imaging Core (MIC), which will provide imaging tools and analyses for measuring tumor growth, assessing the ability to overcome acquired radiation resistance using combination therapies (e.g., FINs with radiation therapy or immunotherapy), identifying intratumoral hypoxic regions, and evaluating myeloid cell expansion in conferring ferroptosis resistance to chemoradiation therapy. To support the MIC and these three projects, the Administrative Core (AC) will be established as part of the ARTI Center infrastructure that will support, coordinate, and facilitate all activities aimed at achieving and evaluating milestones across the projects and core. The AC will establish and maintain engagement and communication among ARTI Center and ARTNet members and program officials in Aim 1. In Aim 2, the AC will facilitate ARTI Center evaluation, support the timely and quality development and submission of progress reports, and maintain proper and transparent stewardship of funds. The AC will develop and implement an internal solicitation and prioritization process for Pilot and Trans-Network Projects in Aim 3. In Aim 4, the AC will serve as the central infrastructure to build a website and manage data, materials, resources, conflict resolution, and issues of intellectual property for technologies and tools. The multiple Principal Investigators (mPIs) of the ARTI Center, Boyi Gan, PhD and Albert Koong, MD, PhD, will serve as AC Co-Leaders. Under their leadership, the AC will be able to leverage institutional and divisional resources; to establish and maintain an ARTI Center Advisory Committee; to encourage the development of junior faculty, trainees, and students in cancer research; to promote collaborations across ARTNet; and to ensure abidance by the ARTNet governance and resource and data sharing policies. Overall, the AC will be the central juncture for the ARTI Center to integrate with other ARTNet centers as well as other National Cancer Institute-funded programs and initiatives.

管理核心 – 摘要 拟议的获得性治疗和铁抗性 (ARTI) 中心重点关注铁死亡在获得性放射治疗抗性中的作用。放射治疗用于治疗大约 50% 的癌症患者，并且是肺部护理治疗的标准。 ARTI 中心将重点关注这些癌症类型，并包括三个研究项目，项目 1 将重点确定铁死亡在放射治疗获得性抵抗中的机制。项目 2 将测试铁死亡诱导剂 (FIN) 作为放射增敏剂，以确定缺氧诱导的铁死亡抵抗是否有助于获得性肿瘤对放射治疗的抵抗，以及 FIN 是否使缺氧肿瘤细胞对放射治疗重新敏感。基因组和微环境因素在食管腺癌放化疗获得性铁死亡抵抗中的作用这三个研究项目将由其中一个项目支持。共享分子成像核心（MIC），它将提供成像工具和分析，用于测量肿瘤生长、评估使用联合疗法（例如，FINs联合放射疗法或免疫疗法）克服获得性放射抗性的能力、识别肿瘤内缺氧区域以及评估骨髓细胞为了支持 MIC 和这三个项目，将建立管理核心 (AC)，作为 ARTI 中心的一部分，授予基础设施，以支持、协调、促进旨在实现和评估跨项目和核心里程碑的所有活动。在目标 1 中，AC 将建立并维持 ARTI 中心和 ARTNet 成员以及项目官员之间的参与和沟通。在目标 2 中，AC 将促进 ARTI 中心的评估，支持及时、高质量地制定和提交进度报告，并保持适当和透明的资金管理。审计委员会将为目标 3 中的试点和跨网络项目制定和实施内部征集和优先排序流程。在目标 4 中， AC 将作为建立网站并管理数据、材料、资源、冲突解决以及技术和工具知识产权问题的中央基础设施。 Albert Koong 博士将担任 AC 联合领导人，在他们的领导下，AC 将能够利用机构和部门资源建立和维持 ARTI 中心咨询委员会，以鼓励初级教师和学员的发展； ，以及从事癌症研究的学生；促进整个 ARTNet 的合作；并确保遵守 ARTNet 治理以及资源和数据共享政策。总体而言，AC 将成为 ARTI 中心与其他 ARTNet 中心以及其他国家癌症研究所资助的项目整合的中心枢纽。和建议。